Company: FENC
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001558370-25-007748
Chunk: 6

Company: FENNEC PHARMACEUTICALS INC.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part II, Item 1L
Chunk 6
---
 to focus the ANDA litigation against CIPLA on the US ‘018 Patent and the US ‘793 Patent only. The non-asserted patents remain listed in the Orange Book. On July 22, 2024, CIPLA filed a response indicating that they do not oppose our Motion for Leave to File a Third Amended Complaint. On July 30, 2024, the court granted us leave to file the Third Amended Complaint, which we filed on September 16, 2024. 

In coordination with the Third Amended Complaint, we entered into a covenant not to sue CIPLA on the US ‘363 Patent, US ‘728 Patent, US ‘984 Patent, US ‘530 Patent, and US ‘604 Patent, subject to the limitation that such shall not apply to the extent CIPLA alters the product or formulation described in its FDA ANDA application. 

​